Puma Biotechnology Stock Fair Value – PUMA BIOTECHNOLOGY Reports Second Quarter FY2023 Earnings Results on August 3 2023
August 29, 2023
🌥️Earnings Overview
On August 3 2023, PUMA BIOTECHNOLOGY ($NASDAQ:PBYI) reported its earnings results for the second quarter of FY2023, which ended on June 30 2023. Revenue for the quarter was USD 54.6 million, down 8.3% year-on-year, while net income amounted to USD 2.1 million, a decrease of 77.3% year-on-year.
Stock Price
At the opening bell, PUMA BIOTECHNOLOGY stock was trading at $3.6, however, it closed at $3.5, down by 2.5% from its last closing price of $3.6. This decline in stock value indicates investors’ cautiousness about PUMA BIOTECHNOLOGY’s earnings results as the company has had a long history of underperforming the market. The company reported lower than expected earnings as well as revenue for the quarter.
Overall, PUMA BIOTECHNOLOGY’s results for the second quarter FY2023 were on the lower side and failed to meet investors’ expectations. Investors’ reaction to the news was negative and the stock price fell shortly after the announcement. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Puma Biotechnology. More…
| Total Revenues | Net Income | Net Margin |
| 230.12 | -2.44 | 4.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Puma Biotechnology. More…
| Operations | Investing | Financing |
| 30.88 | -26.01 | 2.38 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Puma Biotechnology. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 200.49 | 170.09 | 0.65 |
Key Ratios Snapshot
Some of the financial key ratios for Puma Biotechnology are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -1.5% | – | 4.8% |
| FCF Margin | ROE | ROA |
| 4.9% | 24.7% | 3.5% |
Analysis – Puma Biotechnology Stock Fair Value
At GoodWhale we have been analyzing the fundamentals of PUMA BIOTECHNOLOGY and have found that its intrinsic value is around $4.7. This number is derived from our proprietary Valuation Line, which takes into account PUMA BIOTECHNOLOGY’s multiple segments as well as its current profitability and future outlook. We have compared this intrinsic value to the current market price of PUMA BIOTECHNOLOGY’s shares, which are currently trading at around $3.5. This means that the stock is currently undervalued by 26.1% and presents an opportunity for investors to buy in at a discount. More…
Peers
The biopharmaceutical industry is highly competitive, with companies vying for market share in the development and commercialization of innovative therapies. In the field of cancer treatment, Puma Biotechnology Inc has emerged as a leader, with its groundbreaking therapy neratinib (Nerlynx) approved for the treatment of HER2-positive breast cancer. However, the company faces stiff competition from Genmab A/S, UroGen Pharma Ltd, and Mesoblast Ltd, all of which are developing their own innovative cancer therapies.
– Genmab A/S ($LTS:0MGB)
Genmab A/S is a publicly traded Danish biotechnology company. As of May 2020, it had a market capitalization of US$18.38 billion. The company focuses on the development and commercialization of innovative antibody-based therapies for the treatment of cancer and other serious diseases. Genmab’s portfolio includes two commercially available products, Darzalex (daratumumab) and Arzerra (ofatumumab), and a broad pipeline of antibody-based therapeutics in clinical and pre-clinical development.
– UroGen Pharma Ltd ($NASDAQ:URGN)
UroGen Pharma Ltd is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies to treat urological conditions. The company’s products include UroLift System, a minimally invasive treatment for enlarged prostate, and VESIcare, a treatment for overactive bladder.
UroGen Pharma’s market cap is 269.93M as of 2022. The company has a Return on Equity of 191.74%.
The company’s products are designed to improve the lives of patients suffering from urological conditions. The company’s products are backed by clinical data and have the potential to change the standard of care for urological conditions.
– Mesoblast Ltd ($ASX:MSB)
Mesoblast Limited is a global leader in the development and commercialization of innovative cellular medicines. The company has a diversified portfolio of products in clinical and commercial stages. Mesoblast’s products are based on its proprietary mesenchymal lineage adult stem cell technology.
Mesoblast has a market capitalization of 732.9 million as of 2022 and a return on equity of -9.2%. The company’s products are based on its proprietary mesenchymal lineage adult stem cell technology. Mesoblast is a global leader in the development and commercialization of innovative cellular medicines.
Summary
PUMA BIOTECHNOLOGY has reported its earnings results for the second quarter of FY2023, posting total revenue of USD 54.6 million and net income of USD 2.1 million. Year-on-year results have seen a decrease of 8.3% and 77.3% respectively. Investor sentiment towards the company should be cautious given the lacklustre earnings results, as further potential dips in revenue and income could lead to further losses for investors. Nevertheless, the company may still have good prospects in the long-term depending on their ability to improve these figures going forward.
Related Posts
Recent Posts
